IgG4-related sclerosing disease is an immune-mediated disease that affects multiple organs at the same time in some people. This can often include an inflamed pancreas, organ swelling, disease in ...

IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-mediated disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B cells and may be effective for ...

Beamon set out on a journey, and 26 doctors, 37 procedures and more than 17 years later, a rheumatologist finally cracked the confounding code: She had immune disorder IgG4-related disease ...

B-cell depletion with inebilizumab reduced flare risk for pancreatic and/or biliary IgG4-related disease. It also reduced overall glucocorticoid use for disease control in both groups. SAN DIEGO ...

Related Disease - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of historical and ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10% of ...

Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, ...

(Albany, USA) DelveInsight's "IgG4-related disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of IgG4-related disease, historical and ...

WASHINGTON — The B-cell depleting agent inebilizumab (Uplizna) dramatically reduced the risk of flares and increased year-long remission of IgG4-related disease (RD), new research has found.

About Immunoglobulin G4-related disease (IgG4-RD) UPLIZNA is a humanized monoclonal antibody (mAb) that causes targeted and sustained depletion of key cells that contribute to underlying disease ...

Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for rilzabrutinib, a novel, ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved ...